Peringatan Keamanan

LD50 orally in rats: 12000 mg/kg L1410

Talniflumate

DB09295

small molecule experimental

Deskripsi

Talniflumate, is an anti-inflammatory molecule studied and used as a mucin regulator in the treatment of cystic fibrosis, chronic obstructive pulmonary disease (COPD) and asthma L1400. In addition, it is used in inflammatory conditions such as rheumatoid arthritis. Phase I trials with talniflumate for the treatment of cystic fibrosis and COPD were completed in August 2001, and phase II trials were performed in Ireland for the treatment of cystic fibrosis but this research has now been discontinued L1402, L1405. Talniflumate has been approved for approximately 20 years in Argentina other countries (excluding the United States, Europe, and Japan) L1405.

Struktur Molekul 2D

Berat 414.34
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) Approximately 2h in 12 subjects [A31964]
Volume Distribusi In 12 subjects after a single oral administration, total plasma clearance of the main metabolite, niflumic acid, averaged 45 ml/min giving a distribution volume of 0.12 l/kg on average [A31964].
Klirens (Clearance) This drug undergoes extensive first pass effect.

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Extensive liver metabolism.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

1404 Data
Amlodipine Talniflumate may decrease the antihypertensive activities of Amlodipine.
Phentermine The risk or severity of hypertension can be increased when Phentermine is combined with Talniflumate.
Midodrine The risk or severity of hypertension can be increased when Midodrine is combined with Talniflumate.
Eletriptan The risk or severity of hypertension can be increased when Eletriptan is combined with Talniflumate.
Isoetharine The risk or severity of hypertension can be increased when Isoetharine is combined with Talniflumate.
Ziprasidone The risk or severity of hypertension can be increased when Ziprasidone is combined with Talniflumate.
Methysergide The risk or severity of hypertension can be increased when Methysergide is combined with Talniflumate.
Cabergoline The risk or severity of hypertension can be increased when Cabergoline is combined with Talniflumate.
Zolmitriptan The risk or severity of hypertension can be increased when Zolmitriptan is combined with Talniflumate.
Dihydroergotamine The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Talniflumate.
Methylergometrine The risk or severity of hypertension can be increased when Methylergometrine is combined with Talniflumate.
Norepinephrine The risk or severity of hypertension can be increased when Norepinephrine is combined with Talniflumate.
Mirtazapine The risk or severity of hypertension can be increased when Mirtazapine is combined with Talniflumate.
Phenylephrine The risk or severity of hypertension can be increased when Phenylephrine is combined with Talniflumate.
Phenylpropanolamine The risk or severity of hypertension can be increased when Phenylpropanolamine is combined with Talniflumate.
Promazine The risk or severity of hypertension can be increased when Promazine is combined with Talniflumate.
Droperidol The risk or severity of hypertension can be increased when Droperidol is combined with Talniflumate.
Doxapram The risk or severity of hypertension can be increased when Doxapram is combined with Talniflumate.
Atropine The risk or severity of hypertension can be increased when Atropine is combined with Talniflumate.
Lisuride The risk or severity of hypertension can be increased when Lisuride is combined with Talniflumate.
Linezolid The risk or severity of hypertension can be increased when Linezolid is combined with Talniflumate.
Metaraminol The risk or severity of hypertension can be increased when Metaraminol is combined with Talniflumate.
Furazolidone The risk or severity of hypertension can be increased when Furazolidone is combined with Talniflumate.
Epinephrine The risk or severity of hypertension can be increased when Epinephrine is combined with Talniflumate.
Thioridazine The risk or severity of hypertension can be increased when Thioridazine is combined with Talniflumate.
Ergotamine The risk or severity of hypertension can be increased when Ergotamine is combined with Talniflumate.
Nicergoline The risk or severity of hypertension can be increased when Nicergoline is combined with Talniflumate.
Sufentanil The risk or severity of hypertension can be increased when Sufentanil is combined with Talniflumate.
Methoxamine The risk or severity of hypertension can be increased when Methoxamine is combined with Talniflumate.
Risperidone The risk or severity of hypertension can be increased when Risperidone is combined with Talniflumate.
Tranylcypromine The risk or severity of hypertension can be increased when Tranylcypromine is combined with Talniflumate.
Isoflurane The risk or severity of hypertension can be increased when Isoflurane is combined with Talniflumate.
Propiomazine The risk or severity of hypertension can be increased when Propiomazine is combined with Talniflumate.
Alfentanil The risk or severity of hypertension can be increased when Alfentanil is combined with Talniflumate.
Minaprine The risk or severity of hypertension can be increased when Minaprine is combined with Talniflumate.
Orciprenaline The risk or severity of hypertension can be increased when Orciprenaline is combined with Talniflumate.
Propofol The risk or severity of hypertension can be increased when Propofol is combined with Talniflumate.
Phenmetrazine The risk or severity of hypertension can be increased when Phenmetrazine is combined with Talniflumate.
Trifluoperazine The risk or severity of hypertension can be increased when Trifluoperazine is combined with Talniflumate.
Pseudoephedrine The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Talniflumate.
Benzphetamine The risk or severity of hypertension can be increased when Benzphetamine is combined with Talniflumate.
Ritodrine The risk or severity of hypertension can be increased when Ritodrine is combined with Talniflumate.
Flupentixol The risk or severity of hypertension can be increased when Flupentixol is combined with Talniflumate.
Remifentanil The risk or severity of hypertension can be increased when Remifentanil is combined with Talniflumate.
Bitolterol The risk or severity of hypertension can be increased when Bitolterol is combined with Talniflumate.
Oxymetazoline The risk or severity of hypertension can be increased when Oxymetazoline is combined with Talniflumate.
Diethylpropion The risk or severity of hypertension can be increased when Diethylpropion is combined with Talniflumate.
Salmeterol The risk or severity of hypertension can be increased when Salmeterol is combined with Talniflumate.
Naratriptan The risk or severity of hypertension can be increased when Naratriptan is combined with Talniflumate.
Formoterol The risk or severity of hypertension can be increased when Formoterol is combined with Talniflumate.
Frovatriptan The risk or severity of hypertension can be increased when Frovatriptan is combined with Talniflumate.
Methoxyflurane The risk or severity of hypertension can be increased when Methoxyflurane is combined with Talniflumate.
Selegiline The risk or severity of hypertension can be increased when Selegiline is combined with Talniflumate.
Ergoloid mesylate The risk or severity of hypertension can be increased when Ergoloid mesylate is combined with Talniflumate.
Isoprenaline The risk or severity of hypertension can be increased when Isoprenaline is combined with Talniflumate.
Arbutamine The risk or severity of hypertension can be increased when Arbutamine is combined with Talniflumate.
Dutasteride The risk or severity of hypertension can be increased when Dutasteride is combined with Talniflumate.
Halothane The risk or severity of hypertension can be increased when Halothane is combined with Talniflumate.
Moclobemide The risk or severity of hypertension can be increased when Moclobemide is combined with Talniflumate.
Pergolide The risk or severity of hypertension can be increased when Pergolide is combined with Talniflumate.
Desflurane The risk or severity of hypertension can be increased when Desflurane is combined with Talniflumate.
Bromocriptine The risk or severity of hypertension can be increased when Bromocriptine is combined with Talniflumate.
Finasteride The risk or severity of hypertension can be increased when Finasteride is combined with Talniflumate.
Aripiprazole The risk or severity of hypertension can be increased when Aripiprazole is combined with Talniflumate.
Isocarboxazid The risk or severity of hypertension can be increased when Isocarboxazid is combined with Talniflumate.
Ergometrine The risk or severity of hypertension can be increased when Ergometrine is combined with Talniflumate.
Lisdexamfetamine The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Talniflumate.
Fenoterol The risk or severity of hypertension can be increased when Fenoterol is combined with Talniflumate.
Pirbuterol The risk or severity of hypertension can be increased when Pirbuterol is combined with Talniflumate.
Ephedra sinica root The risk or severity of hypertension can be increased when Ephedra sinica root is combined with Talniflumate.
Ephedrine The risk or severity of hypertension can be increased when Ephedrine is combined with Talniflumate.
Mephentermine The risk or severity of hypertension can be increased when Mephentermine is combined with Talniflumate.
Procaterol The risk or severity of hypertension can be increased when Procaterol is combined with Talniflumate.
Yohimbine The risk or severity of hypertension can be increased when Yohimbine is combined with Talniflumate.
Methotrimeprazine The risk or severity of hypertension can be increased when Methotrimeprazine is combined with Talniflumate.
Clenbuterol The risk or severity of hypertension can be increased when Clenbuterol is combined with Talniflumate.
Bambuterol The risk or severity of hypertension can be increased when Bambuterol is combined with Talniflumate.
MMDA The risk or severity of hypertension can be increased when MMDA is combined with Talniflumate.
Midomafetamine The risk or severity of hypertension can be increased when Midomafetamine is combined with Talniflumate.
2,5-Dimethoxy-4-ethylamphetamine The risk or severity of hypertension can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Talniflumate.
4-Methoxyamphetamine The risk or severity of hypertension can be increased when 4-Methoxyamphetamine is combined with Talniflumate.
4-Bromo-2,5-dimethoxyamphetamine The risk or severity of hypertension can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Talniflumate.
Tenamfetamine The risk or severity of hypertension can be increased when Tenamfetamine is combined with Talniflumate.
Chlorphentermine The risk or severity of hypertension can be increased when Chlorphentermine is combined with Talniflumate.
Dextroamphetamine The risk or severity of hypertension can be increased when Dextroamphetamine is combined with Talniflumate.
Phendimetrazine The risk or severity of hypertension can be increased when Phendimetrazine is combined with Talniflumate.
Solifenacin The risk or severity of hypertension can be increased when Solifenacin is combined with Talniflumate.
Periciazine The risk or severity of hypertension can be increased when Periciazine is combined with Talniflumate.
Acepromazine The risk or severity of hypertension can be increased when Acepromazine is combined with Talniflumate.
Thioproperazine The risk or severity of hypertension can be increased when Thioproperazine is combined with Talniflumate.
Zuclopenthixol The risk or severity of hypertension can be increased when Zuclopenthixol is combined with Talniflumate.
Epicaptopril The risk or severity of hypertension can be increased when Epicaptopril is combined with Talniflumate.
Clorgiline The risk or severity of hypertension can be increased when Clorgiline is combined with Talniflumate.
1-benzylimidazole The risk or severity of hypertension can be increased when 1-benzylimidazole is combined with Talniflumate.
Iproniazid The risk or severity of hypertension can be increased when Iproniazid is combined with Talniflumate.
Nialamide The risk or severity of hypertension can be increased when Nialamide is combined with Talniflumate.
Lysergic acid diethylamide The risk or severity of hypertension can be increased when Lysergic acid diethylamide is combined with Talniflumate.
Dronedarone The risk or severity of hypertension can be increased when Dronedarone is combined with Talniflumate.
Flibanserin The risk or severity of hypertension can be increased when Flibanserin is combined with Talniflumate.
Iloperidone The risk or severity of hypertension can be increased when Iloperidone is combined with Talniflumate.

Target Protein

Prostaglandin G/H synthase 1 PTGS1
Prostaglandin G/H synthase 2 PTGS2
Chloride channel protein ClC-Ka CLCNKA

Referensi & Sumber

Artikel (PubMed)
  • PMID: 15202731
    Knight D: Talniflumate (Genaera). Curr Opin Investig Drugs. 2004 May;5(5):557-62.
  • PMID: 26880801
    Rao CV, Janakiram NB, Madka V, Kumar G, Scott EJ, Pathuri G, Bryant T, Kutche H, Zhang Y, Biddick L, Gali H, Zhao YD, Lightfoot S, Mohammed A: Small-Molecule Inhibition of GCNT3 Disrupts Mucin Biosynthesis and Malignant Cellular Behaviors in Pancreatic Cancer. Cancer Res. 2016 Apr 1;76(7):1965-74. doi: 10.1158/0008-5472.CAN-15-2820. Epub 2016 Feb 15.
  • PMID: 6852999
    Houin G, Tremblay D, Bree F, Dufour A, Ledudal P, Tillement JP: The pharmacokinetics and availability of niflumic acid in humans. Int J Clin Pharmacol Ther Toxicol. 1983 Mar;21(3):130-4.

Contoh Produk & Brand

Produk: 0 • International brands: 8
International Brands
  • Huluma — Myungmoon
  • Somalgen
  • Stofen — Shin poong
  • Talmain — Korea United Pharm
  • Talmen — Daewoo
  • Talniflumate Hanall — Hanall Biopharma
  • Talumat — Taiguk
  • Tariful — KWANG DONG

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul